Healthcare Industry News: Central Venous Catheter
News Release - March 9, 2006
Novation Signs New Technology Agreement With Edwards LifesciencesIRVING, TX--(Healthcare Sales & Marketing Network)--Mar 9, 2006 -- Novation, the health care contracting services company of VHA Inc., and the University HealthSystem Consortium (UHC), has signed a single-source, new technology agreement with Edwards Lifesciences for central venous oximetry catheters, which includes the Edwards PreSep catheters.
The agreement began on Feb.1, 2006 and will run through Jan. 31, 2009. The agreement was awarded through Novation's new-technology evaluation, which accelerates the review process so new and improved technologies do not have to wait for a scheduled competitive bid. The process allows VHA and UHC members speedier access to savings on the latest FDA approved medical technology.
The Edwards PreSep catheters provide central venous oxygen saturation monitoring via a Central Venous Catheter platform allowing for real-time monitoring of a patient's condition and assesses the patient's clinical response to intervention.
"This is our 50th agreement through Novation's innovative technology program, and it represents our ongoing commitment to ensuring that member health care organizations have the latest and emerging health care technologies on contract, thereby improving health care delivery and ultimately patient outcomes," said Cathy Denning, senior director, contract and program services at Novation.
Based in Irving, Texas, Novation was established in January 1998 through a combination of the supply programs of VHA and UHC, two national health care alliances. Novation serves the purchasing needs of more than 2,500 members and affiliates of VHA and UHC. These organizations used Novation contracts to purchase more than $23 billion in supplies in 2004.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.